Treatment with subthreshold doses of caffeine plus trihexyphenidyl fully restores locomotion and exploratory activity in reserpinized rats

Neuroscience Letters

Volumn 367, Issue 3, 2004, Pages 327-331

  Moo Puc, Rosa E ^a   Villanueva Toledo, Jairo ^a   Arankowsky Sandoval, Gloria ^a   Alvarez Cervera, Fernando ^a   Góngora Alfaro, José L ^a,b  

^a Departamento de Neurociencias   (Mexico)

^b Mérida 97225 ^*  (Mexico)

Author keywords

Adenosine antagonist; Anticholinergic; Parkinson's disease; Synergism

Indexed keywords

CAFFEINE; RESERPINE; TRIHEXYPHENIDYL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; EXPLORATORY BEHAVIOR; HYPOKINESIA; INFRARED RADIATION; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SHORT TERM MEMORY;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; PARKINSON DISEASE; RATS; RATS, WISTAR; RESERPINE; TRIHEXYPHENIDYL;

EID: 4444360391     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.06.022     Document Type: Article

References (16)

1. Brocks D.R. Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J. Pharm. Pharmaceut. Sci. 2:1999;39-46
2. Carrillo J.A., Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin. Pharmacokinet. 39:2000;127-153
3. Elvefors A., Nissbrandt H. Reserpine-insensitive dopamine release in the substantia nigra? Brain Res. 557:1991;5-12
4. Fahn S. Medical treatment of Parkinson's disease. J. Neurol. 245(Suppl. 3):1998;15-24
5. S. Fahn, R. Burke, Y. Stern, Antimuscarinic drugs in the treatment of movement disorders, in: S.-M. Aquilonius, P.-G. Gillberg (Eds.), Progress in Brain Research, vol. 84, Elsevier, Amsterdam, 1990, pp. 389-397.
6. Gerlach M., Foley P., Riederer R. The relevance of preclinical studies for the treatment of Parkinson's disease. J. Neurol. 250(Suppl. 1):2003;31-34
7. Kartzinel R., Shoulson I., Calne D.B. Studies with bromocriptine. III. Concomitant administration of caffeine to patients with idiopathic parkinsonism. Neurology. 26:1976;741-743
8. A.E. Kelley, Locomotor activity and exploration, in: A. Sahgal (Ed.), Behavioural Neuroscience. A Practical Approach, IRL Press at Oxford University Press, Oxford, 1993, pp. 1-21.
9. Koller W., Cone S., Herbster G. Caffeine and tremor. Neurology. 37:1987;169-172
10. Moo-Puc R.E., Góngora-Alfaro J.L., Alvarez-Cervera F.J., Pineda J.C., Arankowsky-Sandoval G., Heredia-López F. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology. 45:2003;493-503
11. National Research Council of USA, Guide for the Care and Use of Laboratory Animals, National Academy Press, Washington, DC, 1996, 125 pp.
12. A.G. Sadile, Long-term habituation of θ-related activity components of albino rats in the Làt-maze, in: P.R. Sanberg, K.-P. Ossenkoop, M. Kavaliers (Eds.), Motor Activity and Movement Disorders, Humana Press, Totowa, NJ, 1996, pp. 3-55.
13. Shoulson I., Chase T.N. Caffeine and the antiparkinsonian response to levodopa or piribedil. Neurology. 25:1975;722-724
14. Simon P., Dupuis R., Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav. Brain Res. 61:1994;59-64
15. Smith A. Effects of caffeine on human behavior. Food Chem. Toxicol. 40:2002;1243-1255
16. 1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats. Neurosci. Lett. 346:2003;1-4